Multi-Leu-peptide (triacetaat)

Multi-Leu peptide (ML-peptide) triacetate is a potent inhibitor of PACE4 (Ki=22 nM) . Multi-Leu peptide triacetate can competitively bind to the active site of PACE4 by simulating the substrate sequence of PACE4, thereby inhibiting its catalytic activity. Multi-Leu peptide triacetate can be used to study the specific mechanism of PACE4 in the development of prostate cancer[1].

ML-peptide, Multi-Leucine (ML) -peptide (triacetate)

12352209

Autophagy

Autophagy

COVID-19-immunoregulation

Cancer

98.64

O=C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N)=O)=O)=O)=O)=O)=O)=O)=O)C.CC(O)=O.CC(O)=O.CC(O)=O

C55H106N16O15

1231.53

[1]Łepek T, et al. Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations[J]. European journal of cell biology, 2017, 96 (5) : 476-485.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10422A/Multi-Leu-peptide-triacetate-SDS-MedChemExpress.pdf

Peptides

No Development Reported